Clinical trials: Dual Antiplatelet Therapy
Coronary Artery Disease, Aspirin Resistance
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting
Reactive platelet hyperactivity following coronary artery bypass grafting (CABG) might lead to thrombotic complications and major ischemic cardiac events.
- Trial name
- NCT01159639
- Testing
- Clopidogrel
- Where
- Croatia
- Volunteers
- 200 people
- Sponsor
- University of Zagreb
Acute or Programmed Hip Replacement (Gamma Nail, Total Prosthesis or Throuhg DHS) / Knee Surgery
Assessment of Blood Loss With a Point Of Care Device
Main Objective: The purpose of this study is to demonstrate whether there is a correlation between perioperative blood loss and the degree of platelet inhibition assessed by a point of care assay in patients undergoing hip or…
- Trial name
- BLOOD (NCT01430273)
- Where
- 3 sites in France
- Volunteers
- 28 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Total Occlusion
Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery
Coronary arteries are in charge of oxygen supply for the myocardium. When coronary arteries develop stenosis the coronary blood flow (i.e. oxygen flow) is reduced.
- Trial name
- DAPT-CTO (NCT06175377)
- Testing
- Percutaneous coronary intervention, Short dual Aspirin/Clopidogrel therapy, Long dual Aspirin/Clopidogrel therapy
- Volunteers
- 660 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Platelet Inhibition, Coronary Stent Implantation
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode…
- Trial name
- IDEAL-PCI (NCT01515345)
- Testing
- prasugrel or ticagrelor, Clopidogrel
- Where
- Austria
- Volunteers
- 1,008 people
- Sponsor
- Kaiser Franz Josef Hospital
Coronary Artery Disease
"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
Clopidogrel and Prasugrel are pro-drug necessitating conversion in active metabolites through CYP 450 system (CYP), particularly CYP3A and CYP2C19 isoforms.
- Trial name
- dOPPLER (NCT02028234)
- Testing
- Pantoprazole,, Omeprazole
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Roma La Sapienza
Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI)
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
The study aims to determine the feasibility and clinical utility of incorporating precision medicine approaches, incorporating both cytochrome P450 2C19 (CYP2C19) genotyping and platelet reactivity phenotyping, with standard of…
- Conditions
- Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI, Unstable Angina (UA)
- Trial name
- NCT04090281
- Testing
- CYP2C19 genotyping
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Southern California
Acute Coronary Syndrome
Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
The target population of this interventional study was ACS patients with drug-coated balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet therapy compared with dual antiplatelet therapy alone…
- Trial name
- NCT05750758
- Testing
- rivaroxaban
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
Angina Pectoris, Silent Ischemia
Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy
Prospective, randomized, non-inferiority, multicenter, international study.In total 4000 patients (70 centers in Europe) with de novo lesions in native coronary arteries who meet the eligibility criteria randomized to 6 versus 12…
- Trial name
- NCT00944333
- Testing
- Clopidogrel
- Where
- Italy
- Volunteers
- 1,378 people
- Sponsor
- Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Sickle Cell Disease
A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises.
- Trial name
- NCT00834899
- Testing
- Eptifibatide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Acute Coronary Syndrome
Bleeding in Patients Undergoing CABG (Coronary Artery Bypass Graft) During Dual Antiplatelet Therapy
The aim of the study is to evaluate surgery-related bleeding and mortality in patients needing acute coronary artery bypass grafting with or without valve replacement during dual antiplatelet therapy with aspirin and a P2Y12…
- Trial name
- NCT02030548
- Where
- Austria
- Volunteers
- 144 people
- Sponsor
- Medical University of Graz
Peripheral Arterial Disease
Cilostazol Following Peripheral Endovascular Procedures
To compare the safety and effectiveness of dual anti-platelet therapy with cilostazol 100 mg twice daily and aspirin 100 mg daily versus monotherapy with aspirin 100 mg daily in patients undergoing peripheral angioplasty or…
- Trial name
- CILO-PER (NCT02770274)
- Testing
- Cilostazol, Aspirin
- Where
- 2 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Attikon Hospital
Cardiovascular Diseases
A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)
The objective of this post marketing observational registry is to evaluate clinical outcomes (safety and performance) in an all-comers population with coronary artery disease (CAD) treated with the Polymer Free Sirolimus Eluting…
- Trial name
- NCT06412250
- Where
- 32 sites in India, Italy and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Translumina Therapeutics Pvt Ltd.
Coronary Artery Disease, Acute Coronary Syndrome
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
New-generation metallic drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Chronic Coronary Syndrome, Myocardial Infarction
- Trial name
- PARTHENOPE (NCT04135989)
- Testing
- Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease., Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease., Personalized DAPT duration
- Where
- 13 sites in Italy
- Volunteers
- 2,106 people
- Sponsor
- Federico II University
Acute Coronary Syndrome
Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome
The study is a Randomised Registry-based Clinical Trial (RRCT) to assess whether dual antiplatelet therapy with ticagrelor and ASA compared to ASA alone improves outcome after isolated CABG in patients with acute coronary…
- Trial name
- TACSI (NCT03560310)
- Testing
- Ticagrelor 90mg twice daily and ASA 75-100 mg daily, ASA 75-160 mg daily
- Where
- 22 sites in Denmark, Finland and 3 more
- Volunteers
- 2,201 people
- Sponsor
- Vastra Gotaland Region
Coronary Disease
Web basEd soCial Media tecHnology to Improvement in Adherence to Dual anTiplatelet Therapy Following Drug-Eluting Stent Implantation
Few studies have attempt to improve DAPT adherence through social media. The investigators will explore the prevalence of DAPT discontinuation and prove the hypothesis that using social media will improve DAPT adherence among…
- Trial name
- WeChat (NCT03732066)
- Testing
- Usual Text Messages, Personalized Reminders, Interactive Responses
- Where
- China
- Volunteers
- 760 people
- Sponsor
- Guangdong Provincial People's Hospital
Acute Coronary Syndromes, STEMI
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular…
- Conditions
- Acute Coronary Syndromes, STEMI, NSTEMI, Unstable Angina
- Trial name
- SAPT-ACS (NCT07684742)
- Testing
- Early P2Y12 Inhibitor Monotherapy, Standard Dual Antiplatelet Therapy
- Where
- South Korea
- Volunteers
- 1,900 people
- Sponsor
- Gyeongsang National University Hospital
Coronary Artery Disease, Percutaneous Coronary Intervention
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled, dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and planned percutaneous coronary intervention （PCI） will…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
- Trial name
- NCT03599284
- Testing
- Vicagrel 5mg, Vicagrel 6mg, Vicagrel 7.5mg
- Where
- 27 sites in China
- Volunteers
- 279 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Stable Angina, Unstable Angina
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems…
- Conditions
- Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction
- Trial name
- HOST-IDEA (NCT02601157)
- Testing
- 3-months DAPT, 1-year DAPT
- Where
- 12 sites in South Korea
- Volunteers
- 2,173 people
- Sponsor
- Seoul National University Hospital
Ischemic Stroke, CYP2C19 Polymorphism
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
The goal of this observational study is to use a genetic test to help doctors prescribe the most effective medications after a patient has a stroke. One type of stroke is caused by a blood clot in brain vessels.
- Trial name
- ORCA-AIS (NCT06292117)
- Testing
- CYP2C19 Genotype
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- University of Virginia
Stable Angina, Silent Myocardial Ischemia
Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.
The main objective of the SENIOR study is to establish the efficacy and safety of the everolimus eluting stent with a biodegradable abluminal polymer (SYNERGY II) associated with a short dual antiplatelet therapy (DAPT) in…
- Conditions
- Stable Angina, Silent Myocardial Ischemia, Acute Coronary Syndrome
- Trial name
- SENIOR (NCT02099617)
- Testing
- Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent
- Where
- 44 sites in Belgium, Finland and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Ceric Sàrl